GlassScriptPhysician profile
Evans K Komen
NPI 1003216839
$6,751.47
in general payments reported to CMS, 2019-2025
25 companies · $1,719 in 2025
The $1,719 reported for 2025 was more than what 90% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,285 · 2022: $876 · 2023: $1,337 · 2024: $1,535 · 2025: $1,719.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,479 · Education: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,478.53 |
| Education | $112.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,282.34 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $903.75 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $800.14 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Alkermes, INC. | $709.14 | 2021-2025 | Aristada, Lybalvi |
| Supernus Pharmaceuticals, INC. | $439.81 | 2021-2025 | Qelbree, Qelbree |
| Janssen Pharmaceuticals, INC | $358.36 | 2021-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Teva Pharmaceuticals USA, INC. | $305.99 | 2022-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Corium, LLC | $292.04 | 2022-2025 | Azstarys |
| Neurocrine Biosciences, INC. | $262.93 | 2021-2025 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $236.88 | 2021-2022 | |
| Lundbeck LLC | $224.02 | 2021-2024 | Rexulti |
| Ironshore Pharmaceuticals INC. | $219.01 | 2022-2024 | Jornay Pm |
| Axsome Therapeutics, INC. | $169.25 | 2023-2025 | Auvelity |
| Tris Pharma INC | $98.05 | 2023-2025 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $90.27 | 2021-2023 | Trintellix |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $67.63 | 2025 | Jornay Pm |
| E.R. Squibb & Sons, L.L.C. | $56.80 | 2025 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $54.80 | 2022-2023 | Quviviq |
| Jazz Pharmaceuticals INC. | $48.20 | 2021 | |
| Harmony Biosciences LLC | $40.49 | 2025 | |
| Vanda Pharmaceuticals INC. | $36.11 | 2021 | |
| Merck Sharp & Dohme LLC | $16.13 | 2023 | Belsomra |
| Almatica Pharma LLC | $13.38 | 2022 | |
| Bausch Health US, LLC | $13.28 | 2022 | |
| Eisai INC. | $12.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evans Komen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.